Lack Of Competition Thwarts Roche’s PPMS Bid For Ocrevus At UK’s NICE
Executive Summary
Roche’s Ocrevus is having a rough ride through NICE, the UK health technology appraisal body, because there are no other treatments available to slow down the disease, says the company.
You may also be interested in...
UK NICE Changes Mind On Ocrevus After Roche Drops Price
Health technology assessment body NICE has changed its mind about the use of Ocrevus for treating primary progressive multiple sclerosis after Roche offered a lower price for the drug.
Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus
After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.